Co-Author
This page shows the publications co-authored by Mari Mino-Kenudson and Rebecca Heist.
Connection Strength
1.188
-
MET Exon 14 Skipping in Non-Small Cell Lung Cancer. Oncologist. 2016 Apr; 21(4):481-6.
Score: 0.168
-
Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol. 2013 Feb; 37(2):287-94.
Score: 0.135
-
FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012 Dec; 7(12):1775-1780.
Score: 0.134
-
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 Nov 08; 39(11):1531-1547.e10.
Score: 0.062
-
Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 Jul 30.
Score: 0.061
-
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387.
Score: 0.053
-
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
Score: 0.050
-
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):135-140.
Score: 0.050
-
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.049
-
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
Score: 0.049
-
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. Cancer Discov. 2018 05; 8(5):600-615.
Score: 0.048
-
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. J Thorac Oncol. 2017 10; 12(10):e155-e157.
Score: 0.046
-
Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
Score: 0.045
-
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
Score: 0.043
-
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods. 2015 Jul 15; 83:118-27.
Score: 0.039
-
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014 Jun 01; 74(11):3146-56.
Score: 0.037
-
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
Score: 0.031
-
SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. J Clin Oncol. 2011 May 20; 29(15_suppl):7518.
Score: 0.030
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011 Mar 23; 3(75):75ra26.
Score: 0.030
-
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009 Sep 10; 27(26):4247-53.
Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.